Allison L. Fisher

Allison L. Fisher

Auto-generated profile, based on publicly available information

Allison L. Fisher

Nephrology Division and Endocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in The American Journal of Clinical Nutrition
Verified
Journal Article
Open access
PDF file
AFAllison L Fisher
Allison L Fisher
ENElla Nemeth
Ella Nemeth
During pregnancy, iron needs to increase substantially to support fetoplacental development and maternal adaptation to pregnancy. To meet these iron

17 December 2019 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
VSVeena Sangkhae
Veena Sangkhae
AFAllison L. Fisher
Allison L. Fisher
SWShirley Wong
Shirley Wong
MKMary Dawn Koenig
Mary Dawn Koenig
LTLisa Tussing-Humphreys
Lisa Tussing-Humphreys
ENElla Nemeth
Ella Nemeth
Iron deficiency is common worldwide and is associated with adverse pregnancy outcomes. The increasing prevalence of indiscriminate iron supplementation during pregnancy also raises concerns about the potential adverse effects of iron excess. We examined how maternal iron status affects the delivery of iron to the placenta and fetus. Using mouse models, we documented maternal homeostatic mechanisms which protect the placenta and fetus from maternal iron excess. We determined that under physiological conditions or in iron deficiency, fetal and placental hepcidin does not regulate fetal iron endowment. With maternal iron deficiency, critical transporters mediating placental iron uptake (transferrin receptor 1, TFR1) and export (ferroportin, FPN) were strongly regulated. In mice, not only was TFR1 increased but FPN was surprisingly decreased to preserve placental iron, in the face of fetal iron deficiency. In human placentas from pregnancies with mild iron deficiency, TFR1 was increased but without a change in FPN. However, induction of more severe iron deficiency in human trophoblast in vitro resulted in the regulation of both TFR1 and FPN, similarly to the mouse model. This placental adaptation prioritizing placental iron is mediated by the iron-regulatory protein 1 and is important for the maintenance of mitochondrial respiration, thus ultimately protecting the fetus from the potentially dire consequences of generalized placental dysfunction.

21 August 2018 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
YWYing Wang
Ying Wang
MWMichelle Wehling-Henricks
Michelle Wehling-Henricks
SWSteven S. Welc
Steven S. Welc
AFAllison L. Fisher
Allison L. Fisher
QZQun Zuo
Qun Zuo
JTJames G. Tidball
James G. Tidball
Aging is associated with diminished muscle mass, reductions in muscle stem cell functions, and increased muscle fibrosis. The immune system, especially macrophages, can have important roles in modulating muscle growth and regeneration, suggesting that the immune system may also have significant influences on muscle aging. Moreover, the immune system experiences changes in function during senescence, suggesting that regulatory interaction between muscle cells and the immune system may also change during aging. In this study, we performed bone marrow transplantations between age‐mismatched donor and recipient mice to test the influence of the age of the immune system on muscle aging. Transplantation of young bone marrow cells into old recipients prevented sarcopenia and prevented age‐related change in muscle fiber phenotype. Transplantation of old bone marrow cells into young animals reduced satellite cell numbers and promoted satellite cells to switch toward a fibrogenic phenotype. We also demonstrated that conditioned media from young, but not old, bone marrow cells promoted myoblast proliferation in vitro , and we found that factors released by young bone marrow cells were more supportive of myotube differentiation in vitro . Together, our results demonstrate that aging of bone marrow cells promotes the age‐related reduction of satellite cell number and function and contributes to sarcopenia.—Wang, Y., Wehling‐Henricks, M., Welc, S. S., Fisher, A. L., Zuo, Q., Tidball, J. G. Aging of the immune system causes reductions in muscle stem cell populations, promotes their shift to a fibrogenic phenotype, and modulates sarcopenia. FASEB J. 33, 1415–1427 (2019). www.fasebj.org

5 November 2020 in Blood
Verified
Journal Article
Open access
PDF file
VSVeena Sangkhae
Veena Sangkhae
AFAllison L. Fisher
Allison L. Fisher
KCKristine J. Chua
Kristine J. Chua
PRPiotr Ruchala
Piotr Ruchala
TGTomas Ganz
Tomas Ganz
ENElla Nemeth
Ella Nemeth
Iron disorders are associated with adverse pregnancy outcomes, yet iron homeostatic mechanisms during pregnancy are poorly understood. In humans and rodents, the iron-regulatory hormone hepcidin is profoundly decreased in pregnant mothers, which is thought to ensure adequate iron availability for transfer across placenta. However, the fetal liver also produces hepcidin, which may regulate fetal iron endowment by controlling placental iron export. To determine the relative contribution of maternal vs embryo hepcidin to the control of embryo iron endowment in iron-sufficient or iron-overloaded mice, we generated combinations of mothers and embryos that had or lacked hepcidin. We found that maternal, but not embryonic, hepcidin determined embryo and placental iron endowment in a healthy pregnancy. We further determined that inflammation can counteract pregnancy-dependent suppression of maternal hepcidin. To establish how essential maternal hepcidin suppression is for embryo iron homeostasis, we mimicked the range of maternal hepcidin activity by administering a hepcidin peptide mimetic to pregnant mice. This also allowed us to determine the effect of isolated maternal hepcidin excess on pregnancy, in the absence of other confounding effects of inflammation. Higher doses of hepcidin agonist caused maternal iron restriction and anemia, lower placenta and embryo weight, embryo anemia, and increased embryo mortality. Low agonist doses did not cause maternal anemia but still adversely affected the embryo, causing anemia, tissue iron deficiency (including in the brain), and decreased weight. Our studies demonstrate that suppression of maternal hepcidin during pregnancy is essential for maternal and embryo iron homeostasis and health.

26 September 2022 in American Journal of Hematology
Verified
Journal Article
Closed access
AFAllison L. Fisher
Allison L. Fisher
CWChia‐Yu Wang
Chia‐Yu Wang
YXYang Xu
Yang Xu
KJKole Joachim
Kole Joachim
XXXia Xiao
Xia Xiao
JBJodie L. Babitt
Jodie L. Babitt